Pharmacokinetics, Safety, and Ability to Diminish Leukotriene Synthesis by Zileuton, an Inhibitor of 5-lipoxygenase
Overview
Affiliations
Zileuton is a potent and specific inhibitor of 5-lipoxygenase, the first dedicated enzyme in the metabolism of arachidonic acid to the leukotrienes. The leukotrienes have been implicated in numerous pathological conditions. Zileuton was given to normal human volunteers in single doses of 200 mg to 800 mg. Results of these studies indicated that zileuton was well absorbed orally with an elimination half-life of approximately 2.5 hours. Leukotriene B4 production by ex vivo calcium ionophone stimulated whole blood was inhibited by up to 80% of baseline and correlated with plasma concentrations. Zileuton did not significantly inhibit cyclooxygenase as demonstrated by thromboxane B2 levels. There were no safety concerns that would preclude development.
A Novel Strategy to Mitigate the Hyperinflammatory Response to COVID-19 by Targeting Leukotrienes.
Funk C, Ardakani A Front Pharmacol. 2020; 11:1214.
PMID: 32848802 PMC: 7424064. DOI: 10.3389/fphar.2020.01214.
Jiang X, Hawkins J, Lee J, Lizama C, Bos F, Zape J Nat Commun. 2017; 8(1):128.
PMID: 28743859 PMC: 5527007. DOI: 10.1038/s41467-017-00137-y.
Phenotyping drug polypharmacology via eicosanoid profiling of blood.
Song J, Liu X, Rao T, Chang L, Meehan M, Blevitt J J Lipid Res. 2015; 56(8):1492-500.
PMID: 26022804 PMC: 4513990. DOI: 10.1194/jlr.M058677.
Wong S, Awni W, CAVANAUGH J, Locke C, Dube L Clin Pharmacokinet. 1995; 29 Suppl 2:9-21.
PMID: 8620676 DOI: 10.2165/00003088-199500292-00004.
Lack of pharmacokinetic interaction between zileuton and phenytoin in humans.
Samara E, CAVANAUGH J, Mukherjee D, Granneman G Clin Pharmacokinet. 1995; 29 Suppl 2:84-91.
PMID: 8620675 DOI: 10.2165/00003088-199500292-00012.